Key result
Statins effectively prevent ASCVD events across all patient profiles, but in non-ischaemic heart failure, these events are not the main drivers of death or hospitalization.
Why the study?
Does cholesterol-lowering treatment improve outcomes in patients with heart failure?
Does cholesterol-lowering treatment improve outcomes in patients with heart failure?
Answers are grounded in this paper and cite their sources.
This editorial highlights that while cholesterol-lowering therapies prevent ASCVD events, their overall benefit in heart failure is limited because ASCVD events are not the primary drivers of mortality or hospitalization in non-ischaemic HF.
This editorial refers to ‘PCSK9 inhibition and cardiovascular outcomes by heart failure status: a pooled analysis of SPIRE-1 and SPIRE-2’, by A. Razaghizad et al., https://doi.org/10.1093/ejhf/xuag1661. The effect of low-density lipoprotein cholesterol (LDL-C)-lowering treatment on heart failure (HF) remains a matter of scientific debate. On the one hand, statins improve endothelial function, inflammation, and markers of oxidative stress that are important drivers of the development, progression, and symptoms of HF.2,3 On the other hand, observational epidemiologic data dating back to the early 2000s demonstrated an inverse association of total cholesterol and prognosis in patients with HF, i.e., worse outcomes with lower total cholesterol levels.4,5 This counterintuitive observation was referred to as ‘cholesterol paradox’.6 One possible explanation is that low cholesterol concentration is an innocent bystander of malnutrition, cachexia, and chronic inflammation, rather than the primary driver of increased mortality risk.7 Randomized controlled trials of statins in HF patients provided novel insights. In the CORONA trial, 5011 patients with chronic HF of ischaemic aetiology were randomized to treatment with rosuvastatin or placebo. After a median follow-up of 2.7 years, there was no significant difference in the composite endpoint of death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke, and no difference in all-cause mortality. The number of cardiovascular hospitalizations was lower in the rosuvastatin group.8 In the GISSI-HF study, 4574 patients with chronic HF, irrespective of the aetiology, were randomized to receive rosuvastatin or placebo. After a median follow-up of 3.9 years, there was no difference in all-cause mortality or in the composite endpoint that additionally included cardiovascular hospitalizations. There was also no difference in the occurrence of non-fatal myocardial infarction and non-fatal stroke between the groups.9 A pooled analysis of individual patient data of both trials showed a reduction in the risk of myocardial infarction, which was significant in the group of patients with ischaemic aetiology of HF.10 In the HF populations, the risk of all-cause mortality and cardiovascular death—excluding myocardial infarction and stroke—was much higher than the risk of myocardial infarction or stroke itself, highlighting distinct clinical differences between HF and atherosclerotic cardiovascular disease (ASCVD).10 A large meta-analysis of statin trials in patients predominantly without HF at baseline found that statins exhibit a moderate benefit on first HF hospitalizations.11 In summary, statins appear equally effective in preventing ASCVD events across all patient profiles. However, in non-ischaemic HF, these events are not the main drivers of death or hospitalization (Table 1).
No takes yet. Share an insight, caveat, or question.
Katzmann et al. (2026) conducted an editorial in Heart failure. Statins was evaluated. Statins effectively prevent ASCVD events across all patient profiles, but in non-ischaemic heart failure, these events are not the main drivers of death or hospitalization.
Synapse has enriched 10 related papers. Consider them for comparative context: